GlassScriptPhysician profile
Sarah K Picone
NPI 1902363062
$5,509.96
in general payments reported to CMS, 2019-2025
27 companies · $1,535 in 2025
The $1,535 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $808 · 2022: $988 · 2023: $972 · 2024: $1,207 · 2025: $1,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,713.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,296.12 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $678.41 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $469.40 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $365.66 | 2022-2025 | |
| Amgen INC. | $345.90 | 2021-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $316.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $311.37 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $249.31 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.50 | 2021-2025 | Jardiance, Spiriva Respimat, Synjardy |
| Corcept Therapeutics | $230.18 | 2024-2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $114.39 | 2021 | |
| Esperion Therapeutics, INC. | $109.64 | 2021-2025 | Nexletol |
| Paratek Pharmaceuticals, INC. | $108.17 | 2023-2025 | Nuzyra, Xhance |
| Glaxosmithkline, LLC. | $79.84 | 2023-2025 | Arexvy, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $79.65 | 2024-2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $66.87 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Seqirus USA INC | $60.41 | 2025 | Flucelvax, Fluad |
| Insulet Corporation | $56.04 | 2024 | Omnipod |
| Biohaven Pharmaceutical Holding Company LTD. | $53.07 | 2022 | |
| Amarin Pharma, INC. | $50.24 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $49.91 | 2021 | |
| Axsome Therapeutics, INC. | $40.46 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $38.36 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $36.72 | 2023-2024 | Gardasil 9, Gardasil, Capvaxive |
| Mannkind Corporation | $25.03 | 2023 | Afrezza |
| E.R. Squibb & Sons, L.L.C. | $20.57 | 2024 | Eliquis |
| Mylan Specialty L.P. | $14.24 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Picone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.